Comparing Beta Bionics (NASDAQ:BBNX) and PolyPid (NASDAQ:PYPD)

Beta Bionics (NASDAQ:BBNX) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional and Insider Ownership

26.5% of PolyPid shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Beta Bionics and PolyPid”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$53.03 million	12.20	N/A	N/A	N/A
PolyPid	N/A	N/A	-$29.02 million	($4.97)	-0.57

Beta Bionics has higher revenue and earnings than PolyPid.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Beta Bionics and PolyPid, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	0	3	5	1	2.78
PolyPid	0	0	3	1	3.25

Beta Bionics presently has a consensus target price of $24.83, suggesting a potential upside of 64.46%. PolyPid has a consensus target price of $11.33, suggesting a potential upside of 303.32%. Given PolyPid’s stronger consensus rating and higher possible upside, analysts clearly believe PolyPid is more favorable than Beta Bionics.

Profitability

This table compares Beta Bionics and PolyPid’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beta Bionics	N/A	N/A	N/A
PolyPid	N/A	-624.10%	-129.28%

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.